Quantitative image analysis was performed using Spectrum version 11, based on the FDA-approved algorithms supplied by the manufacturer with modifications as described below.
Human 39-plex kits (EMD Millipore, Billerica, MA, USA) were used in accordance with the recommendations of the manufacturer with modifications as described below.
Immunoprecipitations were performed with the Seize-It Mammalian Primary Antibody Precipitation kit (Pierce, Rockford, IL, USA) and Catch-and-Release (Upstate Biotechnology, Charlottesville, VA, USA) according to the protocols provided by each manufacturer, with modifications.
According to the manufacturers, no modifications were made to these products in terms of chemical composition and manufacturing process during the study period.
Long-time readers may know that I'm no great fan of those sorts of manufacturer-mandated modifications, but HTC has been consciously dialing down the once-overwrought Sense experience into something more subtle and fluid.
In all cases, measurements were performed following the instructions provided by the manufacturers without modifications.
Detection of CTCs and assessment of HER2 status of CTCs were performed by using both AdnaTest BreastCancer™ and the CellSearch™ system in accordance with the instructions of the manufacturers without modifications [ 5, 10, 11].
While the earliest manufacturer label modification took place in September 2007, and soon after (March 2008) FDA publication regarding ongoing safety review of Singulair, FLR demonstrated a drug surveillance and early detection capability few years earlier.
The transfections were performed as suggested by the manufacturer with slight modifications, as described previously [17].
The effect of phosphatase on cell-free TACE catalytic activity was tested according to the manufacturer recommended protocol modifications for inhibitor screening also [49].
